Effervescent ranitidine
This article was originally published in The Tan Sheet
Executive Summary
ANDA suitability petition for effervescent ranitidine product withdrawn by Budd Lake, N.J.-based regulatory consultant Thomas Blake, who had filed the petition on behalf of an unnamed client ("The Tan Sheet" Sept. 15, 1997, p. 14). FDA's recent approval of Warner-Lambert's Zantac Efferdose product "means, of course, that an ANDA would be appropriate for the drug," Blake says. Approval of the unnamed party's ANDA will depend on whether Waxman/Hatch exclusivity is granted to the effervescent Zantac product. Zantac Efferdose was approved Feb. 26 ("The Tan Sheet" March 2, p. 1). The agency has yet to disclose an exclusivity ruling...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning